Investors seeking exposure to cutting-edge life sciences innovations will have a unique opportunity on September 17, 2026, as B2i Digital, Inc. hosts the Life Sciences Virtual Investor Forum. The online event, a B2i Digital Featured Conference, is hosted by Virtual Investor Conferences and features live presentations and Q&A sessions from seven companies spanning oncology, fibrosis, drug delivery, antibiotics, cannabinoid therapeutics, and respiratory imaging.
Presenting companies include Sona Nanotech Inc., Raphael Pharmaceutical, Amplia Therapeutics Ltd., Adaptin Bio, Inc., Acurx Pharmaceuticals, Inc., CytoDyn Inc., and 4DMedical Ltd. Each will deliver a 30-minute live session followed by audience Q&A, with replays available on demand via the B2i Digital and OTC Markets YouTube channels. The lineup showcases a photothermal cancer therapy built on gold nanorods, cannabinoid-based formulations for rheumatoid arthritis and chronic lung inflammation, precision drug delivery technologies targeting tissues behind the blood-brain barrier, a new class of antibiotics for priority pathogens, a humanized monoclonal antibody for solid tumors, a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, and FDA-cleared four-dimensional respiratory imaging.
David Shapiro, Chief Executive Officer of B2i Digital, Inc., emphasized the value of direct engagement: “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind.” This format allows investors to assess management’s responsiveness and strategic vision in real time.
The forum matters because it democratizes access to early-stage and emerging life sciences companies that might otherwise be difficult for individual investors to evaluate. By providing a platform for direct dialogue, B2i Digital and Virtual Investor Conferences bridge the information gap between public companies and the investment community. For the industry, the event highlights key trends such as targeted drug delivery, antimicrobial resistance solutions, and advanced imaging—areas poised for significant growth and impact on patient care.
Event details and presenting company profiles are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum, and registration can be completed at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC. Additional B2i Digital resources are at https://b2idigital.com, and Virtual Investor Conferences information is at https://www.virtualinvestorconferences.com.
For the Long Beach area and beyond, this forum signals the continued vitality of the life sciences sector and the importance of investor education. As these companies advance their pipelines, the outcomes could lead to new treatments and technologies that impact global health. Investors who participate will gain timely insights that may inform their portfolios and support innovation.
